- Corporate inversions transfer the company’s tax residence to another country. There have been zero inversions since the passage of the Trump tax reform in 2017.
- Comparing the regulatory costs and benefits of the last three presidents.
- Since the Biden CMS doesn’t believe in market solutions, they are inviting states to experiment with hospital “global budgets.” Just like Canada?
- 40% of cancers are linked to bad behavior.
- The FTC’s case against PBMs.
- Pro PBMs; anti Pharma.
- The 340B Program … is on track to eventually surpass Medicare Part D spending, becoming the largest federal prescription drug program.
Category: Consumer-Driven Health Care
Study: People Do Not Learn From Failure and Need Taxpayer-Supported Help
A new study found that individuals who believe that people learn from failure, and often succeed after failure, are less empathetic.
Friday Links
- Pharmacist admits he routinely ships medication for Alzheimer’s Disease and other forms of dementia to members on Capitol Hill.
- Zvi Mowshowitz on the Hanson/Alexander debate over the value of health care spending.
- Scott Sumner on how regulation lowers our standard of living.
- WSJ: Medicare paid Medicare Advantage (MA) plans $50 billion for untreated ills.
- Douglas Holtz Eakin: net overpayments in the MA program are small and they are three times worse in traditional Medicare.
- Casey Mulligan: Why raising the price of opioids may cause people to consume more of them.
Thursday Links
- Doctors as holograms. (NYT)
- Study: Nearly one-third of those age 60 or older without cardiovascular disease are using aspirin, even though the risks outweigh its benefits for many of those patients.
- Why we have a debt problem: average revenue as a percent of GDP over the past 50 years = 17.3%. Average spending = 21%. (CBO/WSJ)
- The White House flip flops on gender-affirming medical procedures and then flips again.
- Restrictions on flavor-vaping products cause youths to switch to cigarettes instead.